Market Overview

Supernus Awarded Patents Covering Trokendi XR


Supernus Pharmaceuticals (NASDAQ: SUPN) today announced the issuance of two patents (8,298,576 and 8,298,580) by the US Patent and Trademark Office (USPTO) covering Trokendi XR™, its novel once-daily extended-release topiramate product. Both patents were issued by the USPTO on October 30, 2012.

"This is a very important development for us as we continue to build intellectual property protection for our products. Each of our epilepsy products, Trokendi XR™ and Oxtellar XR™, is now covered by two issued US patents," said Jack A. Khattar, President and CEO of Supernus.

Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions.

See full press release

Posted-In: News Guidance Contracts Management


Related Articles (SUPN)

View Comments and Join the Discussion!

Cyclacel Receives $1.9M Grant

Benzinga's Top Initiations